Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Taddei

Showing results (281-290 of 291) with videos related to

Pageof 30
Sort By:
Nature Medicine|December 5, 2022
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-PreservedStefan D Anker, Javed Butler, Muhammad Shariq Usman, et al.
European Journal of Heart Failure|June 26, 2024
OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registryRiccardo M Inciardi, Muthiah Vaduganathan, Carlo M Lombardi, et al.
The New England Journal of Medicine|September 1, 2020
Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureMilton Packer, Stefan D Anker, Javed Butler, et al.
European Journal of Heart Failure|November 30, 2020
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trialStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
Journal of Hypertension|June 2, 2026
Hypertension in autoimmune rheumatic diseases: a position paper from the European Society of Hypertension working group on small arteries. Part A: pathophysiology, prevalence and cardiovascular risk estimationEugenia Gkaliagkousi, Antonios Lazaridis, Carolina de Ciuceis, et al.
The New England Journal of Medicine|August 27, 2021
Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
Journal of Hypertension|June 2, 2026
Hypertension in autoimmune rheumatic diseases - a position paper from the ESH working group on small arteriesEugenia Gkaliagkousi, Michael Doumas, Antonios Lazaridis, et al.
Trials|January 25, 2013
Blood pressure control and treatment adherence in hypertensive patients with metabolic syndrome: protocol of a randomized controlled study based on home blood pressure telemonitoring vs. conventional management and assessment of psychological determinants of adherence (TELEBPMET Study)Gianfranco Parati, Stefano Omboni, Angelo Compare, et al.
Journal of Hypertension|June 22, 2023
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)Giuseppe Mancia, Reinhold Kreutz, Mattias Brunström, et al.
European Journal of Heart Failure|December 18, 2025
Contemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registryRiccardo M Inciardi, Maurizio Volterrani, Gianluigi Savarese, et al.
Pageof 30

Showing results (281-290 of 291) with videos related to

Sort By:
Pageof 30
Nature Medicine|December 5, 2022
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-PreservedStefan D Anker, Javed Butler, Muhammad Shariq Usman, et al.
European Journal of Heart Failure|June 26, 2024
OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registryRiccardo M Inciardi, Muthiah Vaduganathan, Carlo M Lombardi, et al.
The New England Journal of Medicine|September 1, 2020
Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureMilton Packer, Stefan D Anker, Javed Butler, et al.
European Journal of Heart Failure|November 30, 2020
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trialStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
Journal of Hypertension|June 2, 2026
Hypertension in autoimmune rheumatic diseases: a position paper from the European Society of Hypertension working group on small arteries. Part A: pathophysiology, prevalence and cardiovascular risk estimationEugenia Gkaliagkousi, Antonios Lazaridis, Carolina de Ciuceis, et al.
The New England Journal of Medicine|August 27, 2021
Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
Journal of Hypertension|June 2, 2026
Hypertension in autoimmune rheumatic diseases - a position paper from the ESH working group on small arteriesEugenia Gkaliagkousi, Michael Doumas, Antonios Lazaridis, et al.
Trials|January 25, 2013
Blood pressure control and treatment adherence in hypertensive patients with metabolic syndrome: protocol of a randomized controlled study based on home blood pressure telemonitoring vs. conventional management and assessment of psychological determinants of adherence (TELEBPMET Study)Gianfranco Parati, Stefano Omboni, Angelo Compare, et al.
Journal of Hypertension|June 22, 2023
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)Giuseppe Mancia, Reinhold Kreutz, Mattias Brunström, et al.
European Journal of Heart Failure|December 18, 2025
Contemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registryRiccardo M Inciardi, Maurizio Volterrani, Gianluigi Savarese, et al.
Pageof 30